Fulimetibant

N/A

Report date: 2026/03/11 20:02:12
NME

Base Information

Drug NameFulimetibant
Drug Alias NameBAY-2395840BAY-840
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBradykinin B1 receptor antagonists
TargetsBradykinin B1 receptor
Therapy Area/IndicationsDiabetic peripheral neuropathyDiabetes MellitusEndometriosis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaSlovakiaHungary +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesBayer AG
Inactive CompaniesN/A
Active IndicationsDiabetic peripheral neuropathyDiabetes MellitusNeuralgia +[4] 
Inactive IndicationsEndometriosisRenal Insufficiency

Other Information

ATC CodeN/A
Related LinksN/A